German-Korean Workshop
Mechanisms of Protein Aggregation in Neurodegenerative Diseases
Neurodegenerative diseases are a heterogeneous group of disorders that are characterized by a progressive neuronal loss and cognitive decline. The most prominent members of this class of diseases are Parkinson’s disease, Alzheimer’s disease and frontotemporal dementia. Although these disorders manifest in distinct symptoms, they all share one common neuropathological hallmark: the abnormal accumulation and deposition of specific proteins either inside or outside of neurons within certain brain areas. Consequences of protein aggregation are the loss of physiological protein function as well as the gain of cytotoxic properties inducing neuronal death. To date, the mechanisms that drive protein aggregation are not completely understood, and there is no effective therapy available that could stop or at least slow down the progressive course of neurodegenerative diseases.
This workshop will highlight the molecular mechanisms underlying pathological protein aggregation leading to neurodegeneration and present current research on the development of novel therapeutic strategies in the treatment of neurodegenerative diseases.
For further details please contact: Dr. Josephine Labus
Program - MHH, Lecture Hall N - June 22nd, 2022
| 10:30 – 10:40 | Welcome Frank Bengel (Dean of Research - MHH) |
| 10:40 – 10:45 | Introduction Evgeni Ponimaskin |
| 10:45 – 11:20 | Tau-targeted therapeutics for the treatment of Alzheimer‘s disease Ae Nim Pae |
| 11:20 – 11:45 | Targeting neural proteoglycans to control protein aggregation in aeging and neurodegenerative diseases Alexander Dityatev |
| 11:45 – 12:10 | Tau-BiFC platform to visualize neurotoxic Tau species in the brain Yun Kyung Kim |
| 12:10 – 12:35 | Targeting the serotonin receptor 7 ameliorates Tau pathology and memory deficits Evgeni Ponimaskin |
| 12:35 – 13:45 | LUNCH BREAK |
| 13:45 – 14:20 | Clinical trials in Synucleinopathies and Tauopathies Günter Höglinger |
| 14:20 – 14:45 | Modulation of inflammation and glial activation as therapeutic strategy in amyotrophic lateral sclerosis Susanne Petri |
| 14:45 – 15:10 | Tau acetylation induced by HDAC inhibitors Sungsu Lim |
| 15:10 – 15:35 | The role of serotonin receptors in TDP-43 aggregation Josephine Labus |
| 15:35 – 16:00 | COFFEE BREAK |
| 16:00 – 16:35 | Super-resolution microscopy informs on the molecular architecture of alpha-synuclein inclusions in model systems and in the human brain Tiago Outerio |
| 16:35 – 17:00 | Novel therapeutics for Synucleinopathies, progress towards predictive validity of preclinical trials Franziska Richter Assencio |
| 17:00 – 17:25 | Nuclear bodies and aggregates in SMA and ALS Tobias Schüning |
| 17:25– 17:30 | Concluding remarks Evgeni Ponimaskin |
Some impressions of our workshop
